LENZ Therapeutics just absorbed one of the ugliest single-day drops of its life. The stock fell 21% on May 12 to $7.91. It followed a read-out event the day before that clearly failed to convince investors, and the Street responded with a flurry of target cuts that confirm the damage is fundamental, not technical.
More than half the company's freely traded float is now held short. SI % of Free Float came in at 53.3% on May 12 — virtually unchanged from the prior day and up sharply from 46.6% a week earlier. The size of the short book heading into the event is striking: bears had been rebuilding positions through April, pushing SI % FF back above 53% after a brief dip at end of March. The crash validates that thesis in the short run. Borrow availability has loosened considerably as a direct result of the price collapse. Cost to borrow has fallen from a 30-day average around 1.75% down to just 1.06% — the cheapest it has been in over six weeks — which reflects less urgency in the lending market now that the directional move has played out. The borrow market looks notably less stressed than it did a fortnight ago.
The Street moved swiftly. Piper Sandler downgraded from Overweight to Neutral and slashed the target from $39 to $12 — a frank acknowledgment that the commercial thesis has changed. Citigroup maintained Buy but cut from $26 to $20. HC Wainwright held Buy but trimmed from $48 to $38. The consensus average target of $33.71 sits more than four times the current share price, which — given the rapid and ongoing target reductions — reflects stale numbers rather than genuine conviction at that level. The only consistent read-across from the recent moves is that analysts covering the name are still adjusting downward, and the mean will compress further as revisions continue. The ORTEX short score is elevated at 80.8, placing LENZ in the bottom 3rd percentile of the universe by that measure.
Options traders are leaning the other way. The put/call ratio is just 0.31 — close to its 20-day average of 0.29 and barely a quarter of a standard deviation above it. That is notably different from the cautious posture that typically builds into a binary event; it points to call-heavy positioning, suggesting some participants were betting on a positive outcome. The contrast with the extreme short positioning is worth flagging: short sellers were heavily right; the options book skewed wrong.
Insider activity offers a modestly constructive data point — though the timing matters. The CEO bought 28,089 shares on March 27 at $8.95, with the CFO adding 7,500 shares at $8.57 the same day. The board chair also purchased at the open-market price. Net insider buying over the 90-day window amounts to 41,181 shares at a net cost of roughly $366,000. Those buys were made near current price levels, which is notable — but they predate the May 12 event and the new information it delivered. On the institutional side, FMR (Fidelity) added 3.6 million shares as recently as February, making it the second-largest reported holder at 11.8% of shares. Aberdeen, Franklin Resources, and T. Rowe Price all added positions in Q1. None of that buying has updated post-event.
The next formal milestone is a further earnings event on June 12. Between now and then, the key variables are whether additional analyst revisions arrive to close the gap between paper targets and market price, and whether any of the institutional buyers who built positions above $20 begin to reduce.
See the live data behind this article on ORTEX.
Open LENZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
